methods
Last reviewed 01/2018
The PROGRESS trial was a blinded, placebo-controlled trial of a flexible antihypertensive regimen based on perindopril and the diuretic indapamide. 6105 patients with a history of stroke or TIA and were randomised to treatment or placebo.
Active treatment consisted of 4 mg perindopril daily with indapamide at the discretion of the duty physician. Placebo tablets were identical.
The primary outcome was recurrent stroke, fatal and non-fatal. Analysis was by intention to treat.